BeLeaf Medical’s Post

Since 2009, we've been proud to support our awesome cannabis clients across the USA. While a lot of our work comes from the big states, like California, and New York, our team are talking to hundreds of clients each month from the smaller states. Because of that, we like to think we have gained some insights to the markets in which we operate. Here, in our latest blog post, together with my co-managing partner, Abraham Finberg CPA MBA, I write in our blog below to share some of those insights in to one of the smaller, but still important states. #SouthDakota’s journey towards adult-use sales. Essentially, we review the future of South Dakota cannabis tax and finance for companies currently facing that State's challenging landscape. Advocates in the state are preparing for another battle to legalize adult-use cannabis this year, with two competing initiatives underway, but the future remains uncertain as we navigate the rocky terrain. Read on below! Contact us at info@420CPA.com if you can use some financial insights and perspectives on your tax position in cannabis. #420CPA #cannabis

Since 2009, we've been proud to support our cannabis clients across the USA. While a lot of our work comes from the big states, like California, and New York, our team are talking to hundreds of clients each month from the smaller states. Because of that, we like to think we have gained some insights to the markets in which we operate. Here, in our latest blog post, together with my co-managing partner, Rachel Wright, CPA, MST, we write in our blog below to share some insights into one of the smaller, but still important states. #SouthDakota’s journey towards adult-use sales. Essentially, we review the future of South Dakota cannabis tax and finance for companies currently facing that State's challenging landscape. Advocates in the state are preparing for another battle to legalize adult-use cannabis this year, with two competing initiatives underway, but the future remains uncertain as we navigate the rocky terrain. Read on below! Contact us at info@420CPA.com if you can use some financial insights and perspectives on your tax position in cannabis. #420CPA #cannabis

For anyone in my network that is interested in a "high" level overview of the current federal considerations for cannabis re/de-scheduling. Please check out the most recent edition of Cannabis Musings by Hauser Advisory: What's the deal with rescheduling? A very deep dive with a guest star Shane Pennington + Marc Hauser Send some thoughts and reactions in the comments below 👇 https://lnkd.in/gxRP_Vmk

🌿 Ready to unpack the implications of the DEA's groundbreaking decision? Discover how rescheduling cannabis to Schedule III could reshape the landscape for cannabis research, industry, and beyond. Click to read more! #DEA #CannabisPolicy

The recent announcements surround #CannabisRescheduling has left cannabis enthusiasts and industry professionals alike wondering what comes next 🤷♂️ 🤷♀️ Vicente LLP recently conducted a webinar, "Special Briefing on Cannabis Federal Scheduling Reform," featuring top cannabis lawyers and experts to discuss what the road to rescheduling really looks like. Join us as we dive into the insights from this webinar, addressing your pressing questions about the future of cannabis rescheduling and its impact on the industry. 👇

Great article featuring Dan McKillop, Esq.'s thoughts on the DEA's move to reclassify marijuana as a Schedule III drug—major potential for easing business operations, 280E constraints, and enhancing research opportunities in NJ's cannabis industry. Insightful! #CannabisReform #NJBusiness #HealthcareInnovation

🌿🐉 2024, the Year of the Dragon, and a Bright Future for Cannabis! As we venture into 2024, here are key predictions shaping the cannabis industry:  1. Market Expansion: Expect continued growth in both medical and adult-use markets with new states legalizing cannabis.  2. Federal Rescheduling: Likely shift of cannabis from Schedule 1 to Schedule 3, potentially enhancing cannabis business profitability.  3. Banking Reform Stalls: Don’t anticipate significant federal cannabis banking reforms during the presidential election year.  4. Market Dynamics: New legal markets will enjoy high initial pricing, while established markets may face price constraints.  5. Consumer Segmentation: The industry will see more tailored products, reflecting the evolving cannabis consumer base.  6. East Coast Surge: Strong growth expected, especially in new markets like New York and Florida.  7. Consumption Lounges Growth: Increase in public cannabis consumption venues, with Las Vegas leading.  8. Financial Challenges Persist: The industry will continue grappling with capital constraints and high-interest rates. 2024 stands to reignite the cannabis industry after a challenging 2023, bringing exciting opportunities and growth! Check out the full article 👇 #Mood #CannabisIndustry #2024Predictions #CannabisTrends 🌱🔮

That was a very lively and informative panel discussion with Niklas Kouparanis and Philip Schetter last Thursday! Pls consider below below post and youtube-link in case you want to revisit the panel discussion

“Rescheduling is Not Enough,” NORML Deputy Director Paul Armentano says because the DEA will make the final recommendation, “it is safe to say this process still remains far from over” and emphasized his support for descheduling. #NORML #cannabis #cannabisnews #cannabiscommunity #cannabispolicy #cannabislaw #cannabisresearch #cannabisindustry #medicalcannabis #marijuana #marijuananews #marijuanamovement #medicalmarijuana #legalize #legalizeit #legalization #HHS #DEA #FDA

Pros for Cannabis Operators: 1. Access to Financial Services 2. Expansion of Research Opportunities 3. Interstate Commerce & Market Growth Cons for Cannabis Operators: 1. Regulatory Uncertainty 2. Increased Competition and Consolidation 3. Impact on Social Equity and Justice